OptiSeq™ Pan-Cancer Panel Service (65-Gene)

Sample to Clinical Report within 10 days; Performed in a CLIA-Certified Laboratory

DiaDiaCarta offers a sample-to-report OptiSeq™ Targeted Sequencing cancer diagnostic service at its state-of-the-art CLIA certified facility. The liquid biopsy/FFPE sample prep workflow provides clients with fast turnaround time and accurate VAF detection process. Powered by Qiagen’s Clinical Insight Interpret software suite, variants are classified based on guidelines with a focus on actionable content from drug labels and clinical trials. Information is presented in a final clinical report. The whole process from samples (blood/FFPE) to clinical report is completed within 10 business days in our CLIA laboratory.

OptiSeq™ Pan-Cancer Panel is designed to target 2,900 commonly observed mutational positions (hotspots) from 65 oncogenes and tumor suppressor genes. This panel contains a single pool of 601 primer pairs and the average amplicon length is 145 bp – perfectly suitable for ctDNA and FFDNA sequencing.

OptiSeq™ Pan-Cancer Gene Panel (65 Genes)

ABL1AKT1ALKAPCATMBRAFBRCA1
BRCA2CDH1CDKN2ACSF1RCTNNB1DDR2DNMT3A
EGFRERBB2ERBB3ERBB4EZH2FBXW7FGFR1
FGFR2FGFR3FLT3FOXL2GNA11GNAQGNAS
HNF1AHRASIDH1IDH2JAK2JAK3KDR
KITKRASMAP2K1METMLH1MPLMSH6
MTORNF1NF2NOTCH1NPM1NRASPDGFRA
PIK3CAPIK3R1PTCH1PTENPTPN11RB1RET
SMAD4SMARCB1SMOSRCSTK11TERTTP53
TSC1VHL

Advantages of OptiSeq™ Pan-Cancer Panel Service

samples tested

Liquid biopsy (blood/ccfDNA) and FFPE samples (tissue/DNA)  

Clia-certified

Laboratory developed tests performed in a CLIA certified laboratory  

Fast turnaround time

Sample receipt to clinical report within 10 days. No deep sequencing  

Extremely uniform

100% observed uniformity at ≥ 0.2X mean depth and 97% observed uniformity at ≥ 0.5X

highly sensitive

As low as 1% variant allele frequency (VAF) detection  

Report to Clinicians

Comprehensive clinically significant variants, FDA-approved therapies and clinical trials

Low dna input needed

10ng for detection of somatic mutations (SNP); 100pg for germline mutations

OptiSeq™ Pan-Cancer Panel Service Sample Clinical Report

DiaCarta’s clinical report also includes information regarding variant details, FDA-approved therapies for this indication, therapies associated with resistance, clinical trials, genes tested, methods and limitations and selected citations.

Streamlined Workflow for OptiSeq™ Pan-Cancer Panel

Step 1: Sample prep & QC

Step 2: Target enrichment

Step 3: Library Preparation & QC & Template

Step 4: Sequencing Run

Step 5: Data Analysis

Step 6: Reporting

OptiSeq™ Pan-Cancer Panel Specifications

Service Certification

Service performed in a CLIA-certified laboratory 

Sample Type

Liquid biopsy (blood/cfDNA) and FFPE samples (tissue/DNA)

Species

Human

Recommended DNA Input (Amount)

10ng for detection of somatic mutations (SNP); 100pg for germline mutations

Sequencing Platform

Illumina Sequencers (MiniSeq, MiSeq, NextSeq, HiSeq)

Enrichment Method

Multiplex PCR

Number of Primer Pairs

601

Number of Primer Pools

1

Number of Target Genes

65

Target Region Size (bp)

55199

Amplicon Size

Average 146bp (from 125-175bp)

Sample Multiplexing (at ~2000x mean coverage)

Miseq 2×150 Read Length: ~25 samples
NextSeq Series Mid Output 2×150 Read Length: ~200
NextSeq Series High Output @ 2×150 Read Length: ~600

Coverage Uniformity (at ~ ≥ 0.2x Mean Coverage)

> 95%

On-target Reads % (% reads aligned to target regions out of total aligned reads)

> 95%

Turnaround Time

Sample receipt to clinical report within 10 days

Resources

Need Help?

Call us: +1 (800) 878-6662

Email us: information@diacarta.com

Contact Us!

Ready to Subscribe and Learn?

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X